
According to stock market analyst Frank H. Andersen, last week’s announcement from Neurosearch that the company was writing down the key project Huntexil to 0 is a direct consequence of the company’s inability to secure a partnership deal or any other type of fundraising.
“That’s the way it is. Neurosearch has DKK 88 million in the bank, and according to my estimates it is enough capital to see them through Q1 next year,” the analyst tells Medwatch and adds:
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app